Core Viewpoint - Hainan Haiyao's subsidiary has received approval for the antibiotic "Linezolid Tablets," which will enhance the company's product line and market competitiveness in the high-end antibiotic sector [1] Company Summary - Hainan Haiyao's wholly-owned subsidiary, Haikou Pharmaceutical Factory, has obtained the drug registration certificate for Linezolid Tablets from the National Medical Products Administration [1] - The approval of Linezolid, a bacterial protein synthesis inhibitor, will allow the company to enter the high-end antibiotic market and strengthen its brand influence in the antibiotic field [1] Industry Summary - Linezolid is indicated for the treatment of hospital-acquired pneumonia and community-acquired pneumonia caused by specific sensitive strains of microorganisms [1] - The unique mechanism of Linezolid, which inhibits the binding of mRNA to the ribosome, allows for the formation of the 70S ribosomal complex, providing a competitive edge in antibiotic treatment [1]